DC0-NH2 is the cytotoxic payload of an antibody-drug conjugate (ADC) and functions as a highly potent antitumor agent; it exhibits approximately 1,000-fold greater cytotoxicity than conventional chemotherapeutics such as doxorubicin; it binds to the minor groove of DNA and alkylates adenine residues via its cyclopropylbenzindole (CBI) moiety; it demonstrates potent antiproliferative activity against Ramos, Namalwa, HL60/s, and COLO205 cancer cell lines, with IC50 values of 7 pM and 30 pM against Namalwa and HL60/s cells, respectively, and sub-100 pM inhibition against COLO205 cells.